PSA MTNB Event
This program is now full.
Please join us for our next event!
April 18th, 5:30 pm
The Pyramid Club
1735 Market Street, Philadelphia, PA 19103
Dinner Session: This is an “open” meeting, so you can bring guests that may be interested, including clients. Seating is limited, but we hope to accommodate all.
Program Presenter: Matinas BioPharma Holdings
Matinas BioPharma Holdings, Bedminster, NJ, (MTNB) is a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid crystal drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an oral formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia; and MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
